Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism FABP4 inhibitors(fatty acid binding protein 4 inhibitors), FABP5 inhibitors(Fatty acid binding protein 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Celloram, Inc.Startup |
Active Organization Celloram, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | US | Celloram, Inc.Startup | 08 Jan 2024 |
Inflammation | Discovery | US | Celloram, Inc.Startup | 02 Aug 2023 |